// App-Quantinova.ai

2930 : The Combination of High Total Metabolic Tumor Volume and Poor ECOG Performance Status Defines Ultra-High Risk Diffuse Large B-Cell Lymphoma. Validation across Multiple Cohorts of Large Clinical Trials and in Real World

Researchers

Presenter

  • Catherine Thieblemont

Principal Investigators

  • Ulrich Dhrsen

  • Umberto Vitolo

  • Sally F Barrington

  • Laetitia Vercellino

  • Jan Zaucha

  • Ins Patrocinio Carvalho

  • Gomes da Silva Maria

  • Pierre Decazes

  • Pierre-Julien Viailly

  • Herve Tilly

  • Alina Berriolo-Riedinger

  • Rene-Olivier Casasnovas

  • Andreas Httmann

  • Hajira Ilyas

  • George Mikhaeel

  • Joel Dunn

  • Anne Sgolne Cottereau

  • Christine Schmitz

  • Joseph N. Paulson

  • Tina G Nielsen

  • Michel Meignan

Medical Centers

  • Hospital Saint Antoine, Paris, France

  • Centre Hospitalier Lyon-Sud, LYSARC, PIERRE-BÉNITE Cedex, France

  • University Hospital of Essen, Essen, Germany

  • Candiolo Cancer Institute, FPO-IRCCS, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Torino, Italy

  • Guy's and St. Thomas' Hospital and Kings College, London, Kent, United Kingdom

  • Hospital Saint Antoine, Paris, France

  • Department of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk, Poland

  • Institute of Oncology Francisco Gentil, Endocrinology, Lisboa, Portugal

  • Instituto Portugues de Oncologia de Lisboa, Servico de Hematologia, Lisboa, Portugal

  • CRLCC Henri Becquerel, Rouen, France

  • INSERM U1245, Centre Henri Becquerel, UNIROUEN, University of Normandie, Rouen, France

  • C G F L, Dijon, France

  • Hématologie Clinique and INSERM 1231, CHU Dijon,Dijon,France

  • Department of Hematology, University Hospital, Essen, NRW, Germany

  • King's College London, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

  • Department of Clinical Oncology, Guy’s and St Thomas’ NHS Foundation Trust and Cancer Division, Kings College London, London, United Kingdom

  • Kings College London, London, United Kingdom

  • Nuclear Medicine, APHP Tenon Hospital, PARIS, France

  • Department of Hematology, Universitatsklinikum Essen, Essen, Germany

  • Genentech, Inc., South San Francisico, CA

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • LYSA, Paris, France

Locations

  • France

  • Germany

  • Italy

  • United Kingdom

  • Poland

  • Portugal

  • United Arab Emirates

  • United States

  • Switzerland

Companies

  • Genentech, Inc.

  • F. Hoffmann-La Roche

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • Obinutuzumab

  • Obinutuzumab Intravenous

  • Rituximab

Outcome

  • N/A

Study Design

  • Multinational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved